MendiMAAfsarBOksuzF. Uric acid is a useful tool to predict contrast-induced nephropathy. Angiology. 2017;68(7):627–632.
2.
KayaEBYorgunHCanpolatU. Serum uric acid levels predict the severity and morphology of coronary atherosclerosis detected by multidetector computed tomography. Atherosclerosis. 2010;213(1):178–183.
3.
CanpolatUAytemirKYorgunH. Usefulness of serum uric acid level to predict atrial fibrillation recurrence after cryoballoon-based catheter ablation. Europace. 2014;16(2):1731–1737.
4.
CagliKTurakOCanpolatU. Association of serum uric acid level with blood pressure variability in newly diagnosed essential hypertension. J Clin Hypertens (Greenwich). 2015;17(12):929–935.
5.
CanpolatUCagliKArasDKisacikHLAydogduS. The association of serum uric acid level with coronary collateral circulation should be interpreted together with renal function and cardiovascular medications in stable coronary artery disease. Angiology. 2014;65(3):236–237.
6.
SianosGMorelMAKappeteinAP. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1(2):219–227. Web site. http://www.syntaxscore.com/.
7.
ElbasanZSahinDYGurM. Contrast-induced nephropathy in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Angiology. 2014;65(1):37–42.
8.
FarooqVVergouweYRaberL. Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. Eur Heart J. 2012;33(24):3098–3104.
9.
OzturkDCelikOErturkM. Utility of the logistic clinical syntax score in the prediction of contrast-induced nephropathy after primary percutaneous coronary intervention. Can J Cardiol. 2016;32(2):240–246.
10.
MilionisHJKakafikaAITsouliSG. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 2004;148(4):635–640.
11.
OgataNFujimoriSOkaYKanekoK. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids. 2010;29(4-6):321–324.
12.
AthyrosVGKaragiannisAGanotakisES. Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin. 2011;27(8):1659–1668.
13.
MilionisHJRizosEKostapanosM. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin. 2006;22(6):1123–1131.
14.
ErolTTekinAKatircibasiMT. Efficacy of allopurinol pretreatment for prevention of contrast-induced nephropathy: a randomized controlled trial. Int J Cardiol. 2013;167(4):1396–1399.
15.
DaskalopoulouSSTzovarasVMikhailidisDPElisafM. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des. 2005;11(32):4161–4175.
